Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Harleen Bath

Physician Assistant Washington, DC Physician Assistant

NPI 1568999316 CMS profile 11156426

2150 Pennsylvania Ave Nw, Washington, DC 20037

Open in the dashboard

General payments

$17,829

856 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Harleen Bath of Washington, DC is reported in the CMS Open Payments database as having received $17,829 across 856 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $431 18
2024 General $4,658 199
2023 General $4,850 230
2022 General $4,470 218
2021 General $3,420 191

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harleen Bath
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Harleen Bath were reported at $431. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Harleen Bath Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,420 $132 $37–$438 $132
2022 $4,470 $155 $48–$522 $149
2023 $4,850 $167 $52–$557 $160
2024 $4,658 $178 $55–$600 $164
2025 $431 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,790 183 payments
  2. Lilly USA, LLC $1,395 61 payments
  3. Novartis Pharmaceuticals Corporation $1,194 80 payments
  4. EMD Serono, Inc. $1,116 47 payments
  5. Lundbeck LLC $1,106 50 payments
  6. Biogen, Inc. $947 50 payments
  7. US WorldMeds, LLC $580 13 payments
  8. Pfizer Inc. $494 24 payments
  9. Teva Pharmaceuticals USA, Inc. $489 28 payments
  10. Harmony Biosciences LLC $475 22 payments
  11. Other $6,243 298 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,829 856 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $1,908 95 payments
  2. BOTOX $975 42 payments
  3. EMGALITY $921 38 payments
  4. QULIPTA $822 41 payments
  5. REYVOW $780 33 payments
  6. TYSABRI $739 37 payments
  7. KESIMPTA Neurology $576 39 payments
  8. VYEPTI Neurology $555 25 payments
  9. VYEPTI Neurology $530 24 payments
  10. KESIMPTA Neuroscience $527 35 payments
  11. Other $10,371 503 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

659

Median for Physician Assistant: 241

Drug cost

$126,374

Median for Physician Assistant: $4,110

Branded share of claims

27.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 12 $40,874
Qulipta Atogepant Brand 16 $25,927
Emgality Pen Galcanezumab-Gnlm Brand 19 $20,942
Rytary Carbidopa/Levodopa Brand 11 $15,687
Memantine Hcl Er Memantine Hcl Brand 23 $5,168
Rivastigmine Generic 12 $4,207
Carbidopa-Levodopa Carbidopa/Levodopa Brand 64 $1,928
Gabapentin Generic 77 $1,851
Mirtazapine Generic 66 $1,625
Memantine Hcl Generic 42 $1,585

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 45 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Gocovri
$523 — —
BOTOX
$423 — —
UBRELVY
$253 12 —
QULIPTA
$251 16 —
KESIMPTA
$213 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 45 with Patron

Records

856 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record